Stoneridge (SRI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of nine directors, with board recommendations for each nominee.
Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.
Advisory approval of 2025 executive compensation (say-on-pay) is up for vote.
Amendment to the 2025 Long-Term Incentive Plan to increase shares available for issuance.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Director nominees include Aron R. English, Ira C. Kaplan, Kim Korth, William M. Lasky, Natalia Noblet, Carsten J. Reinhardt, Sheila Rutt, Frank S. Sklarsky, and James Zizelman.
Latest events from Stoneridge
- Annual meeting covers director elections, auditor ratification, compensation, and ESG oversight.SRI
Proxy filing9 Apr 2026 - 2025 outperformed end markets with 69%–70% MirrorEye growth and strong 2026 targets.SRI
Q4 202512 Mar 2026 - Q2 2024 saw margin gains, EPS growth, and updated guidance as key tech launches accelerated.SRI
Q2 20242 Feb 2026 - Control Devices sold for $59M to focus on advanced electronics and reduce debt.SRI
Status update2 Feb 2026 - MirrorEye and Smart 2 drive growth through innovation, safety, and regulatory compliance.SRI
CL King’s 22nd Annual Best Ideas Conference 202420 Jan 2026 - Q3 sales and earnings declined, but cash flow and MirrorEye adoption showed improvement.SRI
Q3 202417 Jan 2026 - Growth driven by MirrorEye, Smart 2, and operational improvements despite market softness.SRI
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - MirrorEye/Mirai and Smart 2 growth offset market declines, driving margin and cash flow gains.SRI
Q4 202426 Dec 2025 - Margin gains and record product sales drive Q1, with guidance reaffirmed despite net loss.SRI
Q1 202524 Dec 2025